Global Immunology Market 2018-2022

  • ID: 4450056
  • Report
  • Region: Global
  • 117 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Angimmune
  • Boston Biomedical
  • Cellectar Biosciences
  • F. Hoffmann-La Roche
  • HANSOH
  • MORE
About Immunology

The immune system protects the body from harmful things such as a virus, germs, and diseases like cancer. It is a network of cells, molecules: and organs present throughout the body. The immune system attacks the foreign substance that is found in the body. The body identifies and destroys the abnormal cells including cancerous cells. The inherent self-defense system comprises cells, which help the body in the identification of foreign molecules. Different pathways regulate various immune cells for distinguishing body's healthy cells and disease-causing foreign agents such as a virus: parasite, bacteria, fungi, and cancerous cells. To maintain the body's defense against the continuously evolving organisms, which try to attack the body in numerous ways, continuous modification of all the components of the immune system is essential. Sometimes, the continuously modifying immune system reacts against the body's cells, considering them as foreign agents, which results in the destruction of healthy tissues and becomes the cause of autoimmune diseases and cancers. The inherent state of unresponsiveness may also be observed due to the weakened body defense owing to the genetic reasons that result in immunodeficiency disease.

The analysts forecast the global immunology market to grow at a CAGR of 4.57% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global immunology market for 2018-2022. To calculate the market size, the report considers the revenue generated from the immunology.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Immunology Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
Other prominent vendors
  • Angimmune
  • Bionor Pharma
  • Boston Biomedical
  • Celgene
  • Cellectar Biosciences
  • eFFECTOR Therapeutics
  • Forty Seven
  • HANSOH
  • Immatics Biatechnologies
  • lmmunovaccine
  • Karyopharm Therapeutics
  • MabVax Therapeutics
  • MedImmune
  • MOLOGEN
  • Neon Therapeutics
  • NewLink Genetics
  • Novartis
  • ONCOQUEST
  • Oncotherapeutics.
Market drivers
  • Growing cases of infectious diseases
  • For a full, detailed list, view the full report
Market trends
  • Significant pipeline
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Angimmune
  • Boston Biomedical
  • Cellectar Biosciences
  • F. Hoffmann-La Roche
  • HANSOH
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY CATEGORY
  • Segmentation by category
  • Comparison by category
  • Global immunosuppressants market
  • Global immuno boosters market
  • Market opportunity by category
PART 10: MARKET SEGMENTATION BY INDICATION
  • Autoimmune diseases
  • Oncology
  • Organ transplantation
  • Others
PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Immunology market in Americas
  • Immunology market in EMEA
  • Immunology market in APAC
  • Market opportunity
PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 15: MARKET TRENDS
  • Significant pipeline
  • Collaborations and partnerships for R&D
  • Advanced diagnostic technologies
PART 16: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 17: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
PART 18: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global immunology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global immunology market 2017-2022 ($ billions)
Exhibit 09: Global immunology market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global immunology market by category 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Immunosuppressant drugs
Exhibit 23: Global immunosuppressants market 2017-2022 ($ billions)
Exhibit 24: Global immunosuppressants market: Year-over-year growth 2018-2022 (%)
Exhibit 25: Classification of immuno boosters
Exhibit 26: Global immuno boosters market 2017-2022 ($ billions)
Exhibit 27: Global immuno boosters market: Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by category
Exhibit 29: Brief history of immuno-oncology
Exhibit 30: Stages of anti-tumor immune response
Exhibit 31: Customer landscape
Exhibit 32: Global immunology market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Immunology market in Americas 2017-2022 ($ billions)
Exhibit 35: Immunology market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: Immunology market in EMEA 2017-2022 ($ billions)
Exhibit 38: Immunology market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: Immunology market in APAC 2017-2022 ($ billions)
Exhibit 41: Immunology market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Rise in organ transplantation in US 2015-2016
Exhibit 45: Organ transplantation by donor type 2016
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie: Vendor overview
Exhibit 52: AbbVie: Business segments
Exhibit 53: AbbVie: Organizational developments
Exhibit 54: AbbVie: Geographic focus
Exhibit 55: AbbVie: Segment focus
Exhibit 56: AbbVie: Key offerings
Exhibit 57: Amgen: Vendor overview
Exhibit 58: Amgen: Business segments
Exhibit 59: Amgen: Organizational developments
Exhibit 60: Amgen: Geographic focus
Exhibit 61: Amgen: Segment focus
Exhibit 62: Amgen: Key offerings
Exhibit 63: F. Hoffmann-La Roche: Vendor overview
Exhibit 64: F. Hoffmann-La Roche: Business segments
Exhibit 65: F. Hoffman-La Roche: Organizational developments
Exhibit 66: F. Hoffmann-La Roche: Geographic focus
Exhibit 67: F. Hoffmann-La Roche: Segment focus
Exhibit 68: F. Hoffmann-La Roche: Key offerings
Exhibit 69: Johnson & Johnson: Vendor overview
Exhibit 70: Johnson & Johnson: Business segments
Exhibit 71: Johnson & Johnson: Organizational developments
Exhibit 72: Johnson & Johnson: Geographic focus
Exhibit 73: Johnson & Johnson: Segment focus
Exhibit 74: Johnson & Johnson: Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Angimmune
  • Boston Biomedical
  • Cellectar Biosciences
  • F. Hoffmann-La Roche
  • HANSOH
  • MORE
New Report Released: – Global Immunology Market 2018-2022

The author of the report recognizes the following companies as the key players in the global immunology market: AbbVie, Amgen, F. Hoffmann-La Roche, and Johnson & Johnson.

Other Prominent Vendors in the market are: Angimmune, Bionor Pharma, Boston Biomedical, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics, Forty Seven, HANSOH, Immatics Biatechnologies, lmmunovaccine, Karyopharm Therapeutics, MabVax Therapeutics, MedImmune, MOLOGEN, Neon Therapeutics, NewLink Genetics, Novartis, ONCOQUEST, and Oncotherapeutics.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is significant pipeline. There are multiple promising immunological agents in the pipeline, which boost the market growth after their approval. The approval of new therapeutic agents broadens the options available for the treatment and thus leads to the increase in demand for the therapeutic regimen. There are approximately 51 molecules under different clinical trial stages globally. Out of them, 22 molecules are in Phase II, four molecules are in Phase III, 16 molecules are in Phase I, and remaining are in Phase I/Il clinical trials. One of the most promising molecules under development from AbbVie is risankizumab (ABBY-066). Boehringer Ingelheim and AbbVie are jointly working on the molecule to get approval for new indications such as psoriasis, psoriatic arthritis, and Crohn's disease. This combination is currently going through Phase III clinical trial for psoriasis and Phase II for psoriatic arthritis and Crohn's disease.”

According to the report, one of the major drivers for this market is growing cases of infectious diseases. Infectious diseases such as hepatitis and acquired immunodeficiency syndrome (AIDS) are rampant globally. When the body’s immune system is unable to resist the invading pathogens or microbes, it gives way to infections. Infectious diseases such as hepatitis and AIDS can be treated by immunomodulators. Agents that help in boosting the immunity of the human body help in resisting pathogens. According to the CDC, there are more than a million AIDS-affected people in the US. With the rising incidences of infectious diseases, the demand for immunology products will increase in the coming years.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Angimmune
  • Bionor Pharma
  • Boston Biomedical
  • Celgene
  • Cellectar Biosciences
  • eFFECTOR Therapeutics
  • Forty Seven
  • HANSOH
  • Immatics Biatechnologies
  • lmmunovaccine
  • Karyoph
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll